Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
Phase 3
Completed
NCT03820986
| Condition | Malignant Melanoma |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Merck Sharp & Dohme LLC |
|---|
| Status | Completed |
|---|
| Enrollment | 674 participants |
|---|
| Interventions | Pembrolizumab, Lenvatinib, Placebo for lenvatinib |
|---|
| Start date | Mar 12, 2019 |
|---|
| Completion date | Jan 18, 2023 |
|---|
| Results posted | Jan 17, 2024 |
|---|
Summary
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced melanoma. The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Overall Survival (OS). For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Up to approximately 34 months · Months
| Pembrolizumab+Lenvatinib | 9.1 Months |
|---|
| Pembrolizumab+Placebo | 4.2 Months |
|---|
| p-value | 0.0176 |
|---|
| Hazard Ratio (HR) | 0.81 (95% CI 0.67–0.98) |
|---|
Overall Survival (OS)
Up to approximately 46 months · Months
| Pembrolizumab+Lenvatinib | 25.8 Months |
|---|
| Pembrolizumab+Placebo | 39.5 Months |
|---|
| p-value | 0.9521 |
|---|
| Hazard Ratio (HR) | 1.20 (95% CI 0.97–1.48) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.